IOV-COM-202: lifileucel and pembrolizumab in IO-naive advanced melanoma
RCC Content Hub
Andrew Furness, MD, PhD, Royal Marsden Hospital, London, UK, discusses final results from cohort 1A of the IOV-COM-202 study (NCT03645928), which evaluated lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, combined with pembrolizumab as front-line treatment in advanced melanoma. The combination produced deep and durable responses, including complete responses, with safety consistent with the known profiles of the regimen. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.